Detail akcie Molecular Sp ADS online

Business Summary: Molecular Partners AG is a Switzerland-based clinical-stage biotech company developing DARPin (Designed Ankyrin Repeat Proteins) a new class of custom-built protein therapeutics based on natural binding proteins that open a new dimension of multi-functionality and multi-target specificity in drug design. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.
Financial Summary: BRIEF: For the six months ended 30 June 2023, Molecular Partners AG (ADR) revenues decreased 98% to SF3.5M. Net loss totaled SF30.8M vs. income of SF148.6M. Revenues reflect Switzerland segment decrease of 98% to SF3.5M, United States segment decrease from SF9.7M to SF0K. Net loss reflects Net Foreign Exchange Gain decrease from SF2.6M (income) to SF0K, Other financial expenses increase of 80% to SF9K (expense).